A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients.
Animals
Biomarkers, Tumor
Cell Line, Tumor
Cell Survival
/ drug effects
Cisplatin
/ therapeutic use
Drug Resistance, Neoplasm
Female
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Middle Aged
Ovarian Neoplasms
/ drug therapy
Prognosis
Reactive Oxygen Species
/ analysis
Research Design
Retrospective Studies
Sensitivity and Specificity
Transcriptome
Tumor Burden
/ drug effects
Xenograft Model Antitumor Assays
Prognosis
ROS
Scoring system
Serous ovarian Cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
08 Nov 2019
08 Nov 2019
Historique:
received:
16
04
2019
accepted:
24
10
2019
entrez:
10
11
2019
pubmed:
11
11
2019
medline:
9
4
2020
Statut:
epublish
Résumé
To reveal roles of reactive oxygen species (ROS) status in chemotherapy resistance and to develop a ROS scoring system for prognosis prediction in ovarian cancer. We tested the sensitizing effects of ROS elevating drugs to cisplatin (cDDP) in ovarian cancer both in vitro and in vivo. A ROS scoring system was developed using The Cancer Genome Atlas (TCGA) database of ovarian cancer. The associations between ROS scores and overall survival (OS) were analyzed in TCGA, Tothill dataset, and our in-house dataset (TJ dataset). ROS-inducing drugs increased cisplatin-induced ovarian cancer cell injury in vitro and in vivo. ROS scoring system was established using 25 ROS-related genes. Patients were divided into low (scores 0-12) and high (scores 13-25) score groups. Improved patient survival was associated with higher scores (TCGA dataset hazard ratio (HR) = 0.43, P < 0.001; Tothill dataset HR = 0.65, P = 0.022; TJ dataset HR = 0.40, P = 0.003). The score was also significantly associated with OS in multiple datasets (TCGA dataset r ROS status is associated with chemotherapy resistance. ROS score system might be a prognostic biomarker in predicting the survival benefit from ovarian cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
To reveal roles of reactive oxygen species (ROS) status in chemotherapy resistance and to develop a ROS scoring system for prognosis prediction in ovarian cancer.
METHODS
METHODS
We tested the sensitizing effects of ROS elevating drugs to cisplatin (cDDP) in ovarian cancer both in vitro and in vivo. A ROS scoring system was developed using The Cancer Genome Atlas (TCGA) database of ovarian cancer. The associations between ROS scores and overall survival (OS) were analyzed in TCGA, Tothill dataset, and our in-house dataset (TJ dataset).
RESULTS
RESULTS
ROS-inducing drugs increased cisplatin-induced ovarian cancer cell injury in vitro and in vivo. ROS scoring system was established using 25 ROS-related genes. Patients were divided into low (scores 0-12) and high (scores 13-25) score groups. Improved patient survival was associated with higher scores (TCGA dataset hazard ratio (HR) = 0.43, P < 0.001; Tothill dataset HR = 0.65, P = 0.022; TJ dataset HR = 0.40, P = 0.003). The score was also significantly associated with OS in multiple datasets (TCGA dataset r
CONCLUSIONS
CONCLUSIONS
ROS status is associated with chemotherapy resistance. ROS score system might be a prognostic biomarker in predicting the survival benefit from ovarian cancer patients.
Identifiants
pubmed: 31703584
doi: 10.1186/s12885-019-6288-7
pii: 10.1186/s12885-019-6288-7
pmc: PMC6839150
doi:
Substances chimiques
Biomarkers, Tumor
0
Reactive Oxygen Species
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061Subventions
Organisme : National Key Scientific Instrument and Equipment Development Projects of China
ID : 2016YFC1303012
Organisme : National Basic Research Program of China (973 Program)
ID : 2015CB553903
Organisme : National Science-technology Supporting Plan Projects
ID : 2015BAI13B05
Organisme : Chinese National Key Plan of Precision Medicine Research
ID : 2016YFC0902901
Organisme : Nature and Science Foundation of China
ID : 81402163, 81402164, 81472783, 81572569, 81501530, 81671394, 81370469
Organisme : International S&T Cooperation Program of China
ID : 2013DFA31400
Organisme : Research Project of Health and Family Planning Commission of Hubei Province
ID : WJ2015MA001
Commentaires et corrections
Type : ErratumIn
Références
Biomark Insights. 2018 Feb 06;13:1177271918755391
pubmed: 29449774
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Gene. 2004 Aug 4;337:1-13
pubmed: 15276197
Integr Cancer Ther. 2004 Dec;3(4):294-300
pubmed: 15523100
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Nat Commun. 2019 Apr 12;10(1):1704
pubmed: 30979885
Oxid Med Cell Longev. 2015;2015:294303
pubmed: 26273420
Breast Cancer Res Treat. 2011 Jan;125(2):583-9
pubmed: 20830514
Free Radic Res. 2010 May;44(5):479-96
pubmed: 20370557
Oncotarget. 2016 Jan 19;7(3):3245-54
pubmed: 26675546
Cancer Biol Ther. 2008 Dec;7(12):1875-84
pubmed: 18981733
Oxid Med Cell Longev. 2018 May 24;2018:6135739
pubmed: 29977457
Cancer. 2003 Jan 15;97(2):389-404
pubmed: 12518363
PLoS One. 2018 Nov 26;13(11):e0207319
pubmed: 30475821
Biomed Res Int. 2014;2014:574659
pubmed: 25478571
Mol Clin Oncol. 2018 Mar;8(3):391-399
pubmed: 29599981
Cancer Biol Ther. 2011 Jun 1;11(11):950-8
pubmed: 21467840
Sci Rep. 2016 Jun 09;6:27439
pubmed: 27278439
Drug Resist Updat. 2018 May;38:27-43
pubmed: 29857816
J Gynecol Oncol. 2014 Jan;25(1):51-7
pubmed: 24459581
Oxid Med Cell Longev. 2016;2016:4350965
pubmed: 26998193
Adv Cancer Res. 2014;122:1-67
pubmed: 24974178
Tumour Biol. 2017 Sep;39(9):1010428317714634
pubmed: 28933253
Oxid Med Cell Longev. 2017;2017:2597581
pubmed: 28770020
Biochim Biophys Acta Mol Basis Dis. 2017 Sep;1863(9):2355-2362
pubmed: 28673515
Ageing Res Rev. 2013 Jan;12(1):376-90
pubmed: 23123177
Cancer Res. 2001 Mar 1;61(5):1862-8
pubmed: 11280739
Oncotarget. 2016 Jul 5;7(27):42740-42761
pubmed: 27057637
Cell Death Dis. 2017 Jun 22;8(6):e2887
pubmed: 28640251
Cell Metab. 2013 Nov 5;18(5):617-33
pubmed: 23954639
Cell Death Differ. 2019 Jan;26(2):199-212
pubmed: 30538286
J Gynecol Oncol. 2019 Jul;30(4):e65
pubmed: 31074247
Biomedicine (Taipei). 2017 Dec;7(4):23
pubmed: 29130448
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
Cell Syst. 2019 Feb 27;8(2):163-167.e2
pubmed: 30797774